Glenmark Pharma gets USFDA nod for generic version of Olux-E Foam to treat plaque psoriasis

"Glenmark Pharmaceuticals, USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Clobetasol Propionate Foam, 0.05 per cent (emulsion formulation), a generic version of Olux-E Foam, 0.05 per cent, of Mylan" Glenmark Pharma said in a filing.

Delhi: Drug major Glenmark Pharma on Tuesday said it has received final approval from the US health regulator for Clobetasol Propionate Foam, indicated for the treatment of plaque psoriasis.

The approved product is a generic version of Olux-E Foam, 0.05 per cent, of Mylan Pharmaceuticals.

"Glenmark Pharmaceuticals, USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Clobetasol Propionate Foam, 0.05 per cent (emulsion formulation)," Glenmark Pharma said in a filing.

Read Also: Glenmark Pharma to restructure itself into 3 entities in 2019: Chairman Glenn Saldanha

Quoting to IQVIA sales data for the 12 month period ending July 2019, Glenmark said the Olux-E Foam, 0.05 per cent, market achieved annual sales of approximately USD 11.1 million.

Read Also: Glenmark Pharma gets USFDA nod for a generic version of Elidel Cream to treat skin conditions